Published: Nature
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health
Published: The New England Journal of Medicine
Date:
Authors: Aaron S Kelly 1 , Pernille Auerbach 1 , Margarita Barrientos-Perez 1 , Inge Gies 1 , Paula M Hale 1 , Claude Marcus 1 , Lucy D Mastrandrea 1 , Nandana Prabhu 1 , Silva Arslanian 1 , NN8022-4180 Trial Investigators
Abstract:
Background: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity.
Published: Diabetes Care
Date:
Authors: William I Sivitz 1 , Lawrence S Phillips 2 3 , Deborah J Wexler 4 , Stephen P Fortmann 5 , Anne W Camp 6 , Margaret Tiktin 7 , Magalys Perez 6 , Jacqueline Craig 8 , Priscilla A Hollander 9 , Andrea Cherrington 10 , Vanita R Aroda 11 , Meng Hee Tan 12 , Jonathan Krakoff 13 , Neda Rasouli 14 , Nicole M Butera 15 , Naji Younes 15 , GRADE Research Group
Abstract:
We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes.
Published: Diabetes Care
Date:
Authors: Deborah J Wexler 1 , Heidi Krause-Steinrauf 2 , Jill P Crandall 3 , Hermes J Florez 4 , Sophia H Hox 5 , Alexander Kuhn 6 , Ajay Sood 7 , Chantal Underkofler 8 , Vanita R Aroda 6 , GRADE Research Group
Abstract:
GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) is a 36-center unmasked, parallel treatment group, randomized controlled trial evaluating four diabetes medications added to metformin in people with type 2 diabetes (T2DM).
Published: Global Heart
Date:
Authors: Juan P González-Rivas 1 , Jeffrey I Mechanick 2 , Eunice Ugel 3 , María Inés Marulanda 4 , Maritza Duran 5 , Ramfis Nieto-Martínez 6
Abstract:
Cardiovascular health status of the Venezuelan population has not been evaluated. The American Heart Association recommends the Cardiovascular Health Score (CHS) to assess cardiovascular health.
Published: Journal of Comparative Effectiveness Research
Date:
Authors: Stephanie Behringer-Massera 1 , Terysia Browne 2 , Geny George 3 , Sally Duran 3 , Andrea Cherrington 4 , M Diane McKee 2 5 , GRADE Research Group
Abstract:
Recruitment of participants into research studies, especially individuals from minority groups, is challenging; lack of diversity may lead to biased findings.
Published: Primary Care Diabetes
Date:
Authors: Marcos M Lima-Martínez 1 , Carlos Arrau 2 , Saimar Jerez 2 , Mariela Paoli 3 , Juan P González-Rivas 4 , Ramfis Nieto-Martínez 5 , Gianluca Iacobellis 6
Abstract:
LINK TO RESEARCH https://pubmed.ncbi.nlm.nih.gov/27914905/ ABSTRACT Aim: To assess the relationship between 25-hydroxyvitamin D [25(OH)D] blood concentrations in subjects with obesity and type 2 diabetes mellitus (T2D) risk according to the...
Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.
Published: International Journal of Obesity
Date:
Authors: R H Lustig 1 , F Greenway, P Velasquez-Mieyer, D Heimburger, D Schumacher, D Smith, W Smith, N Soler, G Warsi, W Berg, J Maloney, J Benedetto, W Zhu, J Hohneker
Abstract:
To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.